<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of nonalcoholic fatty liver disease in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of nonalcoholic fatty liver disease in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of nonalcoholic fatty liver disease in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Lai, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nonalcohol-associated fatty liver disease (NAFLD) is a spectrum of disease characterized by hepatic steatosis in the absence of excessive alcohol consumption. NAFLD may progress to cirrhosis and is likely an important cause of cryptogenic cirrhosis [<a href="#rid1">1,2</a>].</p><p>This topic will review the treatment and prognosis of NAFLD. The pathogenesis, clinical manifestations, and diagnosis of NAFLD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3596.html" rel="external">"Pathogenesis of nonalcoholic fatty liver disease"</a> and  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a>.)</p><p>Several professional societies have published guidelines on the management of NAFLD, and our approach is generally consistent with these guidelines [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H244507317"><span class="h1">SPECTRUM OF DISEASE</span><span class="headingEndMark"> — </span>NAFLD ranges from the more benign condition of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which is at the more severe end of the spectrum. In NAFL, hepatic steatosis is present without evidence of inflammation, whereas in NASH, hepatic steatosis is associated with lobular inflammation and apoptosis that can lead to fibrosis and cirrhosis [<a href="#rid1">1,2,6,7</a>]. The histologic findings and scoring systems used to grade disease activity in patients with NAFLD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3635.html" rel="external">"Histologic scoring systems for chronic liver disease", section on 'Nonalcoholic fatty liver disease'</a> and  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'Histologic findings'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H54336987"><span class="h2">General measures for all patients</span><span class="headingEndMark"> — </span>The following measures apply to all patients with NAFLD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abstain from alcohol </strong>–<strong> </strong>We suggest that patients refrain from alcohol, and in particular, recommend avoiding heavy alcohol use (ie, &gt;14 drinks per week or &gt;4 drinks on a given day for males and &gt;7 drinks per week or &gt;3 drinks on a given day for females) [<a href="#rid8">8</a>]. Heavy alcohol use is associated with disease progression [<a href="#rid9">9</a>]. Whether light to moderate alcohol consumption is harmful is not as clear, and this is discussed below. In the absence of definitive data, we suggest abstinence from alcohol. (See <a class="local">'Alcohol use'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunizations </strong>–<strong> </strong>Vaccination for hepatitis A virus and hepatitis B virus should be given to patients without serologic evidence of immunity. Additional vaccines for patients with chronic liver disease include pneumococcal vaccination and standard immunizations that are given to the general population (eg, influenza, diphtheria, tetanus boosters)  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 2</a>). Immunization schedules are described separately. (See  <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease", section on 'Vaccines in chronic liver disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modify risk factors for cardiovascular disease</strong> – Patients with NAFLD are at increased risk for cardiovascular disease and often have multiple risk factors for cardiovascular disease (eg, hypertension, hyperlipidemia). (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'Association with other disorders'</a>.)</p><p></p><p class="bulletIndent1">Management of patients with NAFLD and diabetes includes optimization of blood glucose control. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a> and <a class="local">'Patients with NASH and diabetes'</a> below.)</p><p></p><p class="bulletIndent1">Most patients with NAFLD who have hyperlipidemia are candidates for lipid-lowering therapy, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Chronic liver disease'</a> and  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p></p><p class="headingAnchor" id="H1625343976"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>Weight loss is the primary therapy for most patients with NAFLD. We recommend weight loss for all patients with NAFLD who are overweight (body mass index [BMI] ≥25 kg/m<sup>2</sup>) or have obesity (BMI ≥30 kg/m<sup>2</sup>)<sup> </sup>because weight loss can lead to improvement in liver biochemical tests, liver histology, serum insulin levels, and quality of life in patients with NAFLD [<a href="#rid10">10-13</a>]. We begin with lifestyle interventions including diet modification and exercise. For patients who do not meet weight loss goals after six months, we discuss bariatric surgery. Drug therapy is also an option in certain patients.</p><p class="headingAnchor" id="H65549749"><span class="h3">Initial lifestyle interventions</span><span class="headingEndMark"> — </span>We advise patients who are overweight or have obesity to lose five to seven percent of body weight at a rate of 0.5 to 1.0 kg per week (1 to 2 lb per week) through lifestyle modifications including dietary therapy and exercise. For patients with suspected or biopsy-proven NASH, the weight loss goal is higher (7 to 10 percent of body weight). We provide dietary counseling for patients and also refer them to a nutritionist. Lifestyle interventions to promote weight loss are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/115880.html" rel="external">"Strength training for health in adults: Terminology, principles, benefits, and risks", section on 'Nonalcoholic fatty liver disease'</a>.) </p><p>For some patients, weight loss beyond these initial targets may be required. If the serum alanine aminotransferase (ALT) level does not normalize (ALT &lt;20 for females and &lt;30 for males) after achieving the weight loss goal, we advise patients to lose additional weight. (See <a class="local">'Laboratory monitoring'</a> below.)</p><p>For patients with nonalcoholic steatohepatitis (NASH) or advanced fibrosis who do not meet their weight loss goals after six months of lifestyle interventions, we discuss additional options, including bariatric surgery, which is presented below (see <a class="local">'Bariatric surgery'</a> below).</p><p>Several studies suggest that weight loss of at least 5 percent of body weight is necessary to improve hepatic steatosis, although the long-term benefits of such weight loss are unknown. In a meta-analysis of eight trials including 373 patients, losing ≥5 percent of body weight resulted in improvement in hepatic steatosis, while losing of ≥7 percent of body weight was associated with improvement in NALFD activity score (NAS), which is used to grade disease activity [<a href="#rid14">14</a>]. The NAS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'NAFLD activity score'</a>.)</p><p>In another trial including 31 patients with BMI ranging from 25 to 40 kg/m<sup>2</sup> who had biopsy-proven NASH, enrollment in a weight loss and exercise program resulted in greater weight loss after one year compared with a structured education program (9 versus 0.2 percent of body weight) [<a href="#rid11">11</a>]. Patients in the weight loss and exercise group had higher rates of histologic improvement compared with the education group (72 versus 30 percent).</p><p>Increasing physical activity has been linked to a survival benefit for patients with NAFLD [<a href="#rid15">15,16</a>]. In a longitudinal study of the National Health and Nutrition Examination Survey including 2793 individuals with NAFLD, longer duration of physical activity (measured by accelerometers) was associated with lower risk of all-cause mortality during an average follow-up of nearly 11 years (highest quartile of activity compared with lowest quartile: adjusted hazard ratio [aHR] 0.46, 95% CI 0.28-0.75) [<a href="#rid16">16</a>]. In addition, duration of physical activity was associated with lower risk of cardiovascular disease-related mortality (highest quartile of activity compared with lowest quartile: aHR 0.28, 95% CI 0.08-0.98).</p><p class="headingAnchor" id="H3334393788"><span class="h3">Additional treatments</span></p><p class="headingAnchor" id="H3156472179"><span class="h4">Bariatric surgery</span><span class="headingEndMark"> — </span>We refer patients with NASH or advanced fibrosis (but without decompensated cirrhosis) for bariatric surgery if they do not meet their weight loss goals after six months of lifestyle interventions, including two visits for nutritional counseling. Bariatric surgery is a promising approach for patients with NAFLD, and histologic improvement has been observed postoperatively [<a href="#rid17">17-28</a>]. However, worsening fibrosis occurs in some patients following bariatric surgery, and all patients should have their liver biochemical tests monitored postoperatively (eg, at six weeks, three months, and six months after surgery). We also monitor patients with cirrhosis at one month and three months postoperatively for signs of decompensated cirrhosis (eg, ascites, hepatic encephalopathy), which can occur as a result of surgery. (See  <a class="medical medical_review" href="/z/d/html/90469.html" rel="external">"Outcomes of bariatric surgery", section on 'Nonalcoholic fatty liver disease'</a>.)</p><p class="headingAnchor" id="H1189876792"><span class="h4">Drug therapy</span><span class="headingEndMark"> — </span>Pharmacologic therapy can be used to promote weight loss in patients who fail to achieve their goals through diet and exercise alone. Recommendations for the use of drug therapy to promote weight loss vary greatly among clinicians. Some UpToDate contributors do not use drug therapy often, whereas others prescribe medications in selected patients after providing extensive counseling about lifestyle measures. </p><p>We may use a GLP-1 receptor agonist (off-label) for patients with biopsy-proven NASH with fibrosis stage ≥F2 who do not achieve weight loss with lifestyle interventions. We typically begin a GLP-1 receptor agonist (eg, <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">semaglutide</a>, <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a>) with the same dosing that is used for the labeled indication (obesity)  (<a class="graphic graphic_table graphicRef86204" href="/z/d/graphic/86204.html" rel="external">table 1</a>). We titrate the dose to achieve a weight loss goal of 7 to 10 percent of body weight. For such patients, we also continue to promote lifestyle interventions as long-term therapy. (See <a class="local">'Initial lifestyle interventions'</a> above.)</p><p>Drug therapies for weight loss including administration, dosing, and adverse effects are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a>.)</p><p class="headingAnchor" id="H54337183"><span class="h2">Potential pharmacologic therapies</span><span class="headingEndMark"> — </span>Options for pharmacologic, liver-targeted therapy for NAFLD are limited (eg, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, some insulin sensitizers), and we do not use them in all patients. We reserve pharmacologic therapy for patients who do not achieve their weight loss goals and who have biopsy-proven NASH with fibrosis stage ≥2. The approach also depends on whether the patient has diabetes mellitus.</p><p>Pharmacologic therapies have been studied for the treatment of patients with NASH. However, most trials have been too short to determine an impact on important patient-centered clinical outcomes (eg, decompensated cirrhosis), and instead report on surrogate outcomes, such as serum aminotransferases levels or histologic findings, often with conflicting results [<a href="#rid29">29</a>]. </p><p class="headingAnchor" id="H7"><span class="h3">Patients with NASH but without diabetes</span><span class="headingEndMark"> — </span>For patients with biopsy-proven NASH and fibrosis stage ≥2 who do not have diabetes mellitus, we generally suggest <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, at a dose of 800 international units daily. Some studies suggest that vitamin E improves steatosis and inflammation in such patients. However, because data are mixed and there are potential safety concerns with high-dose vitamin E, we discuss the potential risks and benefits of vitamin E therapy and individualize the decision based on patient preference. </p><p>Since the studies showing a benefit of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> did not include patients with diabetes mellitus or decompensated cirrhosis, we do not use vitamin E in such patients. This is consistent with recommendations from the American Association for the Study of Liver Diseases (AASLD) [<a href="#rid3">3</a>]. </p><p>We do not use <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> for patients with NASH but without diabetes mellitus because of its potential adverse effects as discussed below. (See <a class="local">'Patients with NASH and diabetes'</a> below.)</p><p>Some, but not all, randomized trials support the use of <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> for NASH, but the conflicting findings may be related to differences in trial design [<a href="#rid30">30-37</a>]. A meta-analysis that included five trials found no histologic benefits with vitamin E, though there was significant heterogeneity among the studies with respect to the formulation of vitamin E used, the patient population, the duration of treatment, and the addition of lifestyle modifications [<a href="#rid29">29</a>].</p><p>However, the largest randomized trial included in the meta-analysis (<a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> versus <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">Vitamin E</a> versus Placebo for the Treatment of Nondiabetic Patients with NASH) did suggest a benefit with vitamin E. The trial included 247 adults with NASH without diabetes who were randomly assigned to pioglitazone (30 mg daily), vitamin E (800 international units daily), or placebo for 96 weeks [<a href="#rid32">32</a>]. Patients treated with vitamin E were more likely to have improvement in their global histology score compared with patients who received placebo (43 versus 19 percent). A subsequent report from the trial found that improvement in ALT was more common in patients receiving vitamin E compared with placebo (48 versus 16 percent) [<a href="#rid38">38</a>]. This is consistent with observational studies that suggested improvement in aminotransferase levels in patients with NASH who received vitamin E [<a href="#rid39">39</a>]. The potential benefit is thought to be related to its antioxidant properties. (See  <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">"Overview of vitamin E"</a>.)</p><p>High-dose <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> supplementation (≥400 international units per day) has been inconsistently associated with an increase in all-cause mortality. Underlying comorbidities or use of other supplements in patients using higher doses may have confounded the results, making their interpretation uncertain. Therefore, we feel that vitamin E is a reasonable intervention for patients with NASH and fibrosis stage ≥2 who do not have diabetes mellitus. (See  <a class="medical medical_review" href="/z/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'All-cause mortality'</a>.)</p><p>We avoid <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> in male patients with either a personal history or strong family history of prostate cancer. The association of vitamin E supplementation with the risk of prostate cancer is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6949.html" rel="external">"Chemoprevention strategies in prostate cancer", section on 'Vitamin E'</a>.)</p><p class="headingAnchor" id="H54339533"><span class="h3">Patients with NASH and diabetes</span><span class="headingEndMark"> — </span>For patients with diabetes mellitus, the presence of NASH can inform the choice of glucose lowering therapy in some cases. Although initial therapy for type 2 diabetes mellitus is typically with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, which does not improve liver histology [<a href="#rid40">40,41</a>], the beneficial impact on liver histology with certain other insulin-sensitizing agents could be a consideration when choosing a second-line agent for patients with NASH who cannot take metformin or need additional glucose-lowering therapy. In this setting, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> and glucagon-like peptide-1 (GLP-1) receptor agonists are reasonable options.</p><p>In patients with diabetes mellitus and biopsy-proven NASH, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> improves fibrosis as well as inflammation and steatosis. GLP-1 receptor agonists also appear to provide some benefits for patients with NASH. The potential benefits of these drugs must be balanced with their associated adverse effects. For example, use of pioglitazone is limited because it is associated with increased risk of weight gain, heart failure, and fractures. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a> and  <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Adverse effects'</a>.)</p><p>The overall approach to management of blood glucose in type 2 diabetes is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p>Several trials have demonstrated the impact of these agents in patients with NASH:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> – Thiazolidinediones, and specifically pioglitazone, improve liver biochemical and histologic parameters in patients with NASH [<a href="#rid30">30,32,42-48</a>]. The effect of thiazolidinediones on histologic parameters in NASH was examined in a meta-analysis of four trials that compared thiazolidinediones with placebo in 334 patients with NASH [<a href="#rid49">49</a>]. The analysis found that compared with placebo, thiazolidinediones were more likely to improve hepatic histologic parameters such as ballooning degeneration (OR 2.1, 95% CI 1.3-3.4), lobular inflammation (OR 2.6, 95% CI 1.7-4.0), and steatosis (OR 3.4, 95% CI 2.2-5.3). Improvement in fibrosis was not seen when all thiazolidinediones were examined, but when the analysis was limited to three studies that used pioglitazone, there was a significant improvement in fibrosis among patients treated with pioglitazone compared with placebo (OR 1.7, 95% CI 1.0-2.8).</p><p></p><p class="bulletIndent1">It is likely that long-term treatment is required to achieve a clinically important benefit because the improvements seen with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> may reverse if the drug is stopped [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GLP-1 receptor agonists [<a href="#rid50">50-52</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">Liraglutide</a> – In a trial including 52 patients with NASH who were assigned to receive liraglutide or placebo for 48 weeks, an end-of-treatment biopsy was performed in 23 patients in the liraglutide arm and in 22 patients in the placebo arm [<a href="#rid50">50</a>]. NASH resolved in nine patients (39 percent) who received liraglutide, and in two patients (9 percent) who received placebo (RR 4.3; 95% CI 1.0-17). With regard to fibrosis progression, patients who received liraglutide were less likely to have progression of fibrosis (9 versus 36 percent; RR 0.2; 95% CI 0.1-1.0).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">Semaglutide</a> – In a phase 2 trial including 320 patients with biopsy-proven NASH and liver fibrosis of stage F1, F2 or F3, semaglutide (0.4 mg once daily) resulted in higher rates of histologic resolution of NASH compared with placebo after 72 weeks (59 versus 17 percent; OR 6.87, 95% CI 2.60-17.63) [<a href="#rid52">52</a>]. Lower doses of semaglutide (0.1 mg or 0.2 mg once daily) were less effective but were also more likely to result in histologic resolution compared with placebo (40 percent; OR 3.36, 95% CI 1.29-8.86, and 36 percent; OR 2.71, 95% CI 1.06-7.56, respectively). However, rates of improvement in liver fibrosis stage were not significantly different between the treatment groups and placebo. Gastrointestinal side effects (eg, nausea, vomiting) were more frequently reported with semaglutide compared with placebo, although statistical analysis was not provided. Additional data on histologic outcomes and side effects are needed before semaglutide is used routinely for patients with NASH in the absence of other indications (eg, type 2 diabetes mellitus). (See  <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Adverse effects'</a>.)</p><p></p><p>The apparent benefit of certain insulin-sensitizing agents for NAFLD is likely related to the role insulin resistance plays in the development of NAFLD. (See  <a class="medical medical_review" href="/z/d/html/3596.html" rel="external">"Pathogenesis of nonalcoholic fatty liver disease", section on 'Insulin resistance'</a>.) </p><p>We do not use <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> in patients with diabetes because studies showing a benefit from vitamin E did not include these patients [<a href="#rid32">32,38</a>].</p><p class="headingAnchor" id="H54338666"><span class="h3">Therapies with uncertain benefit</span><span class="headingEndMark"> — </span>Other medical therapies have been examined for the treatment of NAFLD, but none has been studied sufficiently to recommend its use as treatment for fatty liver or NASH:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">Atorvastatin</a> – Pilot studies found a benefit from atorvastatin on aminotransferase levels in patients with NAFLD [<a href="#rid53">53,54</a>]. The use of atorvastatin was then examined in a secondary analysis of a trial looking at the effect of atorvastatin, <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>, and <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> on the development of cardiovascular events in healthy adults [<a href="#rid55">55</a>]. Two of the exclusion criteria for the study were diabetes and serum aminotransferases &gt;1.5 times the upper limit of normal. At baseline, 80 patients had NAFLD based upon imaging criteria. After a mean of 3.6 years of follow-up, fewer patients in the treatment arm still had NAFLD compared with the placebo arm (34 versus 70 percent; adjusted OR 0.36, 95% CI 0.16-0.83).</p><p></p><p class="bulletIndent1">However, the conclusions that can be drawn from the trial are limited because patients did not receive <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a> alone, only in combination with <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> and C, because the diagnosis of NAFLD was based upon imaging criteria and not histology, and because the exclusion criteria (diabetes or elevated aminotransferases) limit its generalizability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omega-3 fatty acids</strong> – Studies have suggested a benefit of omega-3 fatty acids in patients with NAFLD [<a href="#rid56">56,57</a>]. In a meta-analysis of nine studies with 355 patients, treatment with omega-3 fatty acids was associated with improvement in hepatic steatosis as well as aspartate aminotransferase levels [<a href="#rid57">57</a>]. There was also a trend toward improvement in alanine aminotransferase levels. When the analysis was restricted to data from randomized trials, only hepatic steatosis continued to show improvement with omega-3 fatty acid treatment [<a href="#rid57">57-60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> – Limited data suggest that daily aspirin use is beneficial for patients with NAFLD [<a href="#rid61">61-63</a>]. In the enrollment phase of a prospective cohort study including 361 patients with biopsy-proven NAFLD, daily aspirin users were less likely to have NASH (adjusted odds ratio [aOR] 0.68, 95% CI 0.37-0.89) and fibrosis (aOR 0.54, 95% CI 0.31-0.82) compared with daily aspirin nonusers [<a href="#rid61">61</a>]. In addition, among 317 patients without advanced fibrosis at baseline, daily aspirin users were less likely to progress to advanced fibrosis compared with nonusers (adjusted hazard ratio 0.63, 95% CI 0.43-0.85) during 3692 person-years of follow-up. These results are promising, and future trials may add to data supporting the hepatoprotective effects of aspirin.</p><p></p><p class="headingAnchor" id="H3044166565"><span class="h2">Laboratory monitoring</span><span class="headingEndMark"> — </span>We obtain serum aminotransferases (ALT and aspartate aminotransferase) every three to six months after patients implement lifestyle interventions to achieve and maintain their weight loss goals. If the aminotransferases do not return to normal levels with weight loss or if they increase, we evaluate the patient for an alternative cause of liver disease. The evaluation of patients with abnormal liver biochemical tests is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.) </p><p class="headingAnchor" id="H150642859"><span class="h2">Monitoring for fibrosis</span><span class="headingEndMark"> — </span>Our approach to monitoring patients for advanced fibrosis depends on whether they have biopsy-proven NASH and if they achieved weight loss goals and normalization of serum aminotransferases:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with biopsy-proven NASH</strong> – For patients with biopsy-proven NASH, we obtain a noninvasive assessment for advanced fibrosis at a time interval determined by their clinical course:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have not been able to lose at least five to seven percent of their body weight and/or have elevated serum aminotransferases, we obtain noninvasive assessment every three years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who achieve their weight loss goals and have normal serum aminotransferases, we obtain noninvasive assessment every four years.</p><p></p><p class="bulletIndent1">If the noninvasive assessment shows a low risk fibrosis score (≤F1), we continue monitoring patients every four years (if weight loss was achieved and maintained) or every three years (if weight loss was not achieved or maintained). Patients with NASH and no fibrosis or minimal fibrosis have an excellent prognosis and thus, close follow-up is not needed [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">If the noninvasive assessment shows an increased, high risk fibrosis score (≥F2) we discuss obtaining a follow-up liver biopsy with the patient to evaluate for advanced fibrosis. If the biopsy does not show cirrhosis, we continue to monitor the patient with noninvasive imaging at intervals as described above. If the liver biopsy shows cirrhosis, further management includes preventing and identifying complications of cirrhosis (eg, variceal hemorrhage, hepatocellular carcinoma), and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without biopsy proven NASH</strong> – We do not routinely obtain a noninvasive assessment for fibrosis in patients with nonalcoholic fatty liver but without biopsy-proven NASH. If the patient’s clinical status subsequently changes (eg, additional weight gain, development of other features of metabolic syndrome), we obtain a noninvasive assessment of fibrosis every three to four years. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)", section on 'Definition'</a>.) </p><p></p><p>The method of noninvasive evaluation depends on the availability, and options include elastography (vibration-controlled transient elastography, ultrasound shear wave or magnetic resonance elastography) and serum fibrosis markers. (See  <a class="medical medical_review" href="/z/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography"</a> and  <a class="medical medical_review" href="/z/d/html/1239.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations", section on 'Imaging examinations'</a>.)</p><p>We monitor patients with vibration-controlled transient elastography (VCTE), a noninvasive, point-of-care tool that can exclude advanced fibrosis based on liver stiffness measurements [<a href="#rid65">65</a>]. In a prospective study of 120 patients with biopsy-proven NAFLD, VCTE correctly identified 74 patients (45 percent) as having low risk for advanced fibrosis. This approach would avoid the need for liver biopsy in these low-risk patients while those at high risk for fibrosis generally require confirmatory biopsy or further imaging. (See  <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults", section on 'Vibration controlled transient elastography'</a>.)</p><p class="headingAnchor" id="H1264492743"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2239973212"><span class="h2">Patients with cirrhosis</span><span class="headingEndMark"> — </span>The management of cirrhosis due to NAFLD is similar to that for cirrhosis due to other causes and includes management of portal hypertension, screening for hepatocellular carcinoma, and evaluation for liver transplantation for patients with decompensated cirrhosis. The approach to managing patients with cirrhosis is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p class="headingAnchor" id="H809207208"><span class="h1">DISEASE COURSE</span></p><p class="headingAnchor" id="H1924148277"><span class="h2">Advanced fibrosis</span><span class="headingEndMark"> — </span>Patients with NAFLD are at risk for advanced fibrosis, defined histologically as stage F2 or higher  (<a class="graphic graphic_table graphicRef98105" data-inline-graphics="98105" href="/z/d/graphic/98105.html" rel="external">table 2</a>). Cirrhosis develops when simple steatosis progresses to steatohepatitis and then to fibrosis. The fibrosis stage is the only measure that correlates with outcomes such as liver-related illness, liver transplantation and liver-related mortality in patients with NAFLD [<a href="#rid64">64,66,67</a>]. (See <a class="local">'Monitoring for fibrosis'</a> above.)</p><p>While the risk of disease progression among patients with NAFLD has been evaluated in multiple studies, the results have been variable, and the risk of developing advanced fibrosis among patients with NAFLD is unclear [<a href="#rid1">1,2,6,7,68-76</a>]. A meta-analysis that included 11 studies looked at progression to fibrosis in 366 patients with NAFLD [<a href="#rid77">77</a>]. Overall, the fibrosis stage progressed in 132 patients (36 percent), remained stable in 158 patients (46 percent), and improved in 76 patients (21 percent). It appears that patients with simple steatosis on biopsy are at lower risk for developing advanced fibrosis, whereas those with nonalcoholic steatohepatitis are at higher risk [<a href="#rid78">78</a>]. In addition, some patients with fibrosis show regression of their disease [<a href="#rid68">68-70</a>]. </p><p>In a cohort study of 129 patients with NAFLD who had two follow-up biopsies in addition to clinical and biochemical evaluations, 12 patients (9 percent) developed symptoms of end-stage liver disease in mean follow-up time of 19.8 years [<a href="#rid6">6</a>]. In 113 patients with baseline low fibrosis (defined as stage &lt;F3), 18 patients (16 percent) developed advanced fibrosis (F3 or F4) by the end of the study period. (See  <a class="medical medical_review" href="/z/d/html/3635.html" rel="external">"Histologic scoring systems for chronic liver disease", section on 'Nonalcoholic fatty liver disease'</a>.)</p><p class="headingAnchor" id="H2850361749"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Factors that have been associated with advanced fibrosis can be classified as patient- or disease-related:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient-related risk factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol use (see <a class="local">'Alcohol use'</a> below).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Body mass index ≥28 kg/m<sup>2</sup> [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes mellitus [<a href="#rid66">66,81</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older age (eg, ≥50 years) [<a href="#rid70">70,82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disease-related risk factors</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologic evidence of inflammation on liver biopsy (see <a class="local">'Hepatic inflammation'</a> below).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ballooning degeneration plus Mallory hyaline or fibrosis on biopsy [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated serum aminotransferases (eg, ≥2 times the upper limit of normal) [<a href="#rid79">79,81-83</a>].</p><p></p><p>Coffee consumption has been associated with a lower risk of progressing to fibrosis [<a href="#rid84">84</a>]. </p><p>Several statistical models have been described to predict fibrosis, but none have been extensively validated [<a href="#rid79">79,83,85-87</a>].</p><p class="headingAnchor" id="H4255143727"><span class="h4">Alcohol use</span><span class="headingEndMark"> — </span>We suggest that patients refrain from alcohol, and in particular, we recommend avoiding heavy alcohol use (ie, &gt;14 drinks per week or &gt;4 drinks on a given day for males and &gt;7 drinks per week or &gt;3 drinks on a given day for females) [<a href="#rid8">8</a>]. (See <a class="local">'General measures for all patients'</a> above and  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment", section on 'Terminology'</a>.)</p><p>Heavy alcohol use among patients with NAFLD has been associated with hepatic steatosis, hepatic injury, and fibrosis progression [<a href="#rid9">9</a>]. In a study of 71 patients with NAFLD followed for a mean of 14 years, 17 patients (24 percent) had fibrosis progression [<a href="#rid9">9</a>]. Heavy episodic drinking (defined in this study as more than 60 grams of alcohol on one occasion for males or 48 grams for females) was more common in those with fibrosis progression than in those without progression (47 versus 11 percent).</p><p>We also suggest that patients with NAFLD abstain from consuming any alcohol. The effect of light or moderate alcohol consumption on disease progression is less clear because data provide mixed results and prospective studies are limited. Some studies suggest that the consumption of as little as two drinks per day in those who are overweight (and one drink per day in those with obesity) is associated in hepatic injury [<a href="#rid88">88-90</a>]. In a cohort study of 285 patients with NAFLD, modest alcohol use, compared to no alcohol use, was also associated with less improvement in steatosis and level of aspartate transaminase as well as decreased chance of NASH resolution. In addition, moderate alcohol consumption does not appear to lower the risk of cardiovascular disease for patients with NAFLD, in contrast to the general population [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p>However, other data suggest that light or moderate alcohol consumption may have beneficial effects on the liver [<a href="#rid92">92,93</a>]. This was seen in a cross-sectional study that compared 251 lifetime nondrinkers with NAFLD with 331 modest drinkers with NAFLD [<a href="#rid92">92</a>]. Modest drinkers had lower odds for fibrosis (OR 0.56; 95% CI 0.41-0.77) and ballooning hepatocellular injury (OR 0.66; 95% CI 0.48-0.92) compared with nondrinkers. </p><p class="headingAnchor" id="H1818232519"><span class="h4">Hepatic inflammation</span><span class="headingEndMark"> — </span>Histologic evidence of hepatic inflammation is an important risk factor for developing advanced fibrosis. In a systematic review that included 187 patients with paired biopsies, the median time to develop advanced fibrosis among those with inflammation on the initial biopsy was 4.2 years, compared with 13.4 years for those without inflammation [<a href="#rid70">70</a>]. After adjusting for potential confounders, the presence of any inflammation on the initial biopsy increased the chance of progressing to advanced fibrosis 2.5-fold compared with patients who did not have inflammation.</p><p class="headingAnchor" id="H2879422334"><span class="h2">Hepatocellular carcinoma</span><span class="headingEndMark"> — </span>Surveillance for hepatocellular carcinoma (HCC) is recommended for patients with NASH-related cirrhosis. Routine surveillance intervals, imaging tests, and management of imaging results are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p>We do not obtain surveillance imaging for patients without cirrhosis, because the risk of HCC-related mortality is low in the absence of cirrhosis.</p><p>Patients with cirrhosis due to NAFLD are at higher risk for HCC compared with patients without cirrhosis [<a href="#rid94">94,95</a>]. In a systematic review of 61 studies and case series of patients with NAFL or NASH, the risk of HCC among those with cirrhosis ranged from 2.4 percent over seven years to 12.8 percent over three years [<a href="#rid94">94</a>]. Among those without cirrhosis, the risk of mortality from HCC was 0 to 3 percent after follow-up periods of up to 20 years.</p><p>It has been shown across different care settings that patients with NASH-related cirrhosis have lower rates of HCC surveillance compared with patients with cirrhosis from other etiologies such as hepatitis C virus infection [<a href="#rid96">96-98</a>].</p><p class="headingAnchor" id="H3190632045"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Whether patients with NAFLD have increased overall mortality rates compared with the general population is not clear. While small population-based studies have suggested a mortality risk [<a href="#rid67">67,99,100</a>], the largest study from the United States suggests that the overall mortality rate is not increased in the absence of fibrosis. The National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2012 included 6000 adults in whom rates of NAFLD and advanced fibrosis, as determined by the NAFLD activity score, were 30 and 10.3 percent, respectively [<a href="#rid101">101</a>]. Compared with individuals without NAFLD, overall mortality was lower in NAFLD participants without fibrosis (HR 0.41, 95% CI 0.22-0.76), while mortality was higher in NAFLD participants with advanced fibrosis (HR 3.13, 95% CI 1.93-5.08). </p><p>Fibrosis stage has been associated with risk of mortality. In a study including 1773 adults with NAFLD who were followed for a median of four years, the risk of all-cause mortality was higher for patients with stage F4 fibrosis (cirrhosis, HR 3.9) and stage F3 fibrosis (bridging fibrosis, HR 1.9) compared with F0 to F2 fibrosis (1.76 and 0.89 deaths per 100 person-years, respectively, versus 0.32 deaths per 100 person-years) [<a href="#rid102">102</a>]. The risk of liver-related mortality was higher for patients with stage F4 fibrosis (HR 12.7) and stage F3 fibrosis (HR 5.8) compared with F0 to F2 fibrosis (0.68 and 0.28 deaths per 100 person-years, respectively, versus 0.04 deaths per 100 person-years). These data underscore the importance of preventing disease progression in patients without advanced fibrosis or cirrhosis and the impact of achieving regression in patients with advanced disease.</p><p>Cardiovascular disease is the most common cause of death among patients with NAFLD. A previous study (NHANES III), which showed similar trends in mortality, found that the increase in mortality in NAFLD patients with fibrosis (as measured by the NAFLD fibrosis score) was due almost exclusively to cardiovascular causes (HR 3.46, 95% CI 1.91-6.25) [<a href="#rid103">103</a>]. Risk factors for cardiovascular disease (eg, diabetes, hyperlipidemia) can be identified and managed in patients with NAFLD. (See <a class="local">'General measures for all patients'</a> above.)</p><p>Patients with NASH are at increased risk for liver-related death compared with patients with fatty liver but without NASH [<a href="#rid67">67,99,104,105</a>].</p><p class="headingAnchor" id="H4196869326"><span class="h2">Liver decompensation</span><span class="headingEndMark"> — </span>Fibrosis stage has been associated with risk of liver decompensation. In a study including 1773 adults with NAFLD who were followed for a median of four years, the risk of new onset hepatic decompensation was higher for patients with stage F4 fibrosis (cirrhosis) and stage F3 fibrosis (bridging fibrosis) compared with F0 to F2 fibrosis (2.69 and 0.99 events per 100 person-years, respectively, versus 0.05 events per 100 person-years) [<a href="#rid102">102</a>]. </p><p class="headingAnchor" id="H53584735"><span class="h1">WHEN TO REFER</span><span class="headingEndMark"> — </span>Referral to a hepatologist is indicated for patients with NAFLD and any of the following features (see <a class="local">'Monitoring for fibrosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Aminotransferases (alanine aminotransferase and aspartate aminotransferase) that remain elevated despite loss of ≥5 percent of body weight (to evaluate for other etiologies of liver disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features of advanced liver disease (eg, ascites, splenomegaly, jaundice)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Steatohepatitis on liver biopsy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced fibrosis (fibrosis stage ≥F3) on a noninvasive liver assessment </p><p></p><p>Patients who develop cirrhosis and have complications (eg, ascites, variceal bleeding) or a model for end-stage liver disease (MELD) score ≥10 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fresources%2Fallocation-calculators%2Fmeld-calculator%2F&amp;token=iRMJIIdlcCMEXBWgyUXhEj85JXUmTLBxW0uB0IuIJz7WR7PrHBxXi2mI3BwjTJvu4iYyowpPMNpkTBUTjvT81BphmAxTsPpJApITG494Mzc%3D&amp;TOPIC_ID=3600" target="_blank">MELDNa score</a>) should be referred for a liver transplantation evaluation. (See  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p class="headingAnchor" id="H2925991330"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116327.html" rel="external">"Society guideline links: Nonalcoholic fatty liver disease"</a>.)</p><p class="headingAnchor" id="H89167656"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16156.html" rel="external">"Patient education: Nonalcoholic fatty liver disease (The Basics)"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4577.html" rel="external">"Patient education: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) (Beyond the Basics)"</a>).</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures </strong>– The following general measures apply to patients with nonalcoholic fatty liver disease (NAFLD) (see <a class="local">'General measures for all patients'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without serologic evidence of immunity, vaccination for hepatitis A virus and hepatitis B virus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Standard, age-appropriate immunizations  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with hyperlipidemia, lipid-lowering therapy. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with diabetes, optimizing blood glucose control. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight management </strong>– We recommend weight loss for patients with obesity (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Weight loss has been associated with histologic improvement in patients with NAFLD. We advise patients to lose a minimum of five to seven percent of body weight at a rate of 0.5 to 1.0 kg per week (1 to 2 lb per week) through lifestyle modifications, including dietary therapy and exercise. (See <a class="local">'Weight loss'</a> above and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoiding alcohol </strong>– For patients with NAFLD, we recommend refraining from heavy alcohol consumption (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>) and suggest abstinence from alcohol (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Heavy alcohol use is associated with alcohol-related liver disease and other adverse consequences, including cancers of the mouth and esophagus. In patients with or at risk for NAFLD, heavy alcohol use is associated with hepatic steatosis, hepatic injury, and fibrosis progression. Whether light to moderate alcohol consumption is harmful remains somewhat uncertain as data are mixed. In the absence of definitive data, we suggest abstinence from alcohol for patients with NAFLD. (See <a class="local">'General measures for all patients'</a> above and <a class="local">'Alcohol use'</a> above and  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with NASH but without diabetes mellitus – For patients with biopsy-proven nonalcoholic steatohepatitis (NASH) and fibrosis stage ≥2 but without diabetes, we suggest using <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> (800 international units per day) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Limited evidence supports a benefit of vitamin E in patients without diabetes, but some observational studies suggest a possible increase in all-cause mortality with higher dose vitamin E. As a result, we discuss the risks and benefits with the patient before starting treatment. (See <a class="local">'Patients with NASH but without diabetes'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with NASH and diabetes mellitus – For patients with NASH and diabetes mellitus, the presence of NASH can inform the choice of glucose-lowering therapy. Although initial therapy for type 2 diabetes mellitus is typically with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, the beneficial impact on liver histology with certain other insulin-sensitizing agents could be a consideration when choosing a second-line agent for patients with NASH who cannot take metformin or need additional glucose-lowering therapy. In this setting, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> and GLP-1 receptor agonists (eg, <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a>, <a class="drug drug_general" data-topicid="115980" href="/z/d/drug information/115980.html" rel="external">semaglutide</a>) are reasonable options. (See <a class="local">'Patients with NASH and diabetes'</a> above and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring </strong>– We obtain serum aminotransferases (alanine aminotransferase and aspartate aminotransferase) three and six months after patients with NAFLD implement lifestyle interventions for weight loss. If the aminotransferases do not return to normal levels with weight loss or if they increase, we evaluate for an alternative cause of liver disease. (See <a class="local">'Laboratory monitoring'</a> above and  <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for fibrosis </strong>– For patients with biopsy-proven NASH, we obtain a noninvasive assessment for advanced fibrosis at a time interval determined by their clinical course (see <a class="local">'Monitoring for fibrosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have not been able to lose at least five to seven percent of their body weight and/or have elevated serum aminotransferases, we obtain a noninvasive assessment every three years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who achieve their weight loss goals and have normal serum aminotransferases, we obtain a noninvasive assessment every four years.</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff thank Dr. Sunil Sheth for his contributions as author to prior versions of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol 2015; 13:2062.</a></li><li><a class="nounderline abstract_t">Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology 2016; 150:1769.</a></li><li><a class="nounderline abstract_t">Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77:1797.</a></li><li><a class="nounderline abstract_t">Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28:528.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388.</a></li><li><a class="nounderline abstract_t">Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatol Commun 2018; 2:199.</a></li><li><a class="nounderline abstract_t">Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15:11.</a></li><li class="breakAll">https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-and-statistics (Accessed on December 26, 2022).</li><li><a class="nounderline abstract_t">Ekstedt M, Franzén LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2009; 44:366.</a></li><li><a class="nounderline abstract_t">Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54:603.</a></li><li><a class="nounderline abstract_t">Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51:121.</a></li><li><a class="nounderline abstract_t">Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57:157.</a></li><li><a class="nounderline abstract_t">Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149:367.</a></li><li><a class="nounderline abstract_t">Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55:885.</a></li><li><a class="nounderline abstract_t">Croci I, Coombes JS, Bucher Sandbakk S, et al. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. Prog Cardiovasc Dis 2019; 62:127.</a></li><li><a class="nounderline abstract_t">Kim D, Murag S, Cholankeril G, et al. Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021; 19:1240.</a></li><li><a class="nounderline abstract_t">Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39:1647.</a></li><li><a class="nounderline abstract_t">Furuya CK Jr, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007; 22:510.</a></li><li><a class="nounderline abstract_t">Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16:1278.</a></li><li><a class="nounderline abstract_t">Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 2012; 22:1016.</a></li><li><a class="nounderline abstract_t">Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13:1180.</a></li><li><a class="nounderline abstract_t">de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006; 16:270.</a></li><li><a class="nounderline abstract_t">Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101:368.</a></li><li><a class="nounderline abstract_t">Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15:1154.</a></li><li><a class="nounderline abstract_t">Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242:610.</a></li><li><a class="nounderline abstract_t">Lassailly G, Caiazzo R, Buob D, et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology 2015; 149:379.</a></li><li><a class="nounderline abstract_t">Lee Y, Doumouras AG, Yu J, et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019; 17:1040.</a></li><li><a class="nounderline abstract_t">Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401:1786.</a></li><li><a class="nounderline abstract_t">Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52:79.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2:1107.</a></li><li><a class="nounderline abstract_t">Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:2485.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675.</a></li><li><a class="nounderline abstract_t">Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537.</a></li><li><a class="nounderline abstract_t">Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100:1082.</a></li><li><a class="nounderline abstract_t">Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38:413.</a></li><li><a class="nounderline abstract_t">Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119.</a></li><li><a class="nounderline abstract_t">Ersöz G, Günşar F, Karasu Z, et al. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005; 16:124.</a></li><li><a class="nounderline abstract_t">Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013; 38:134.</a></li><li><a class="nounderline abstract_t">Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734.</a></li><li><a class="nounderline abstract_t">Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32:1211.</a></li><li><a class="nounderline abstract_t">Li Y, Liu L, Wang B, et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2013; 1:57.</a></li><li><a class="nounderline abstract_t">Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46:424.</a></li><li><a class="nounderline abstract_t">Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188.</a></li><li><a class="nounderline abstract_t">Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297.</a></li><li><a class="nounderline abstract_t">Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135:1176.</a></li><li><a class="nounderline abstract_t">Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135:100.</a></li><li><a class="nounderline abstract_t">Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38:1008.</a></li><li><a class="nounderline abstract_t">Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med 2016; 165:305.</a></li><li><a class="nounderline abstract_t">Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35:66.</a></li><li><a class="nounderline abstract_t">Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387:679.</a></li><li><a class="nounderline abstract_t">Cusi K. Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. Hepatology 2019; 69:2318.</a></li><li><a class="nounderline abstract_t">Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384:1113.</a></li><li><a class="nounderline abstract_t">Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57:1711.</a></li><li><a class="nounderline abstract_t">Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16:39.</a></li><li><a class="nounderline abstract_t">Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106:71.</a></li><li><a class="nounderline abstract_t">Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010; 31:679.</a></li><li><a class="nounderline abstract_t">Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56:944.</a></li><li><a class="nounderline abstract_t">Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14:6395.</a></li><li><a class="nounderline abstract_t">Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 2010; 61:792.</a></li><li><a class="nounderline abstract_t">Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40:194.</a></li><li><a class="nounderline abstract_t">Simon TG, Henson J, Osganian S, et al. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2019; 17:2776.</a></li><li><a class="nounderline abstract_t">Yoshida S, Ikenaga N, Liu SB, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 2014; 147:1378.</a></li><li><a class="nounderline abstract_t">Jiang ZG, Feldbrügge L, Tapper EB, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2016; 43:734.</a></li><li><a class="nounderline abstract_t">Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med 2017; 377:2063.</a></li><li><a class="nounderline abstract_t">Tapper EB, Challies T, Nasser I, et al. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2016; 111:677.</a></li><li><a class="nounderline abstract_t">Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149:389.</a></li><li><a class="nounderline abstract_t">Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61:1547.</a></li><li><a class="nounderline abstract_t">Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59:969.</a></li><li><a class="nounderline abstract_t">Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010; 33:284.</a></li><li><a class="nounderline abstract_t">Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51:371.</a></li><li><a class="nounderline abstract_t">Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53:750.</a></li><li><a class="nounderline abstract_t">Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132.</a></li><li><a class="nounderline abstract_t">Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865.</a></li><li><a class="nounderline abstract_t">Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129:375.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43:682.</a></li><li><a class="nounderline abstract_t">Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013; 59:550.</a></li><li><a class="nounderline abstract_t">Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13:643.</a></li><li><a class="nounderline abstract_t">Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012; 10:837.</a></li><li><a class="nounderline abstract_t">Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:1117.</a></li><li><a class="nounderline abstract_t">Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35:238.</a></li><li><a class="nounderline abstract_t">Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1224.</a></li><li><a class="nounderline abstract_t">Noureddin M, Yates KP, Vaughn IA, et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013; 58:1644.</a></li><li><a class="nounderline abstract_t">Francque SM, Verrijken A, Mertens I, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 2012; 10:1162.</a></li><li><a class="nounderline abstract_t">Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55:429.</a></li><li><a class="nounderline abstract_t">Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356.</a></li><li><a class="nounderline abstract_t">Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91.</a></li><li><a class="nounderline abstract_t">Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846.</a></li><li><a class="nounderline abstract_t">Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3:1260.</a></li><li><a class="nounderline abstract_t">Ajmera V, Belt P, Wilson LA, et al. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 2018; 16:1511.</a></li><li><a class="nounderline abstract_t">Blomdahl J, Nasr P, Ekstedt M, Kechagias S. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatol Commun 2023; 7:e0003.</a></li><li><a class="nounderline abstract_t">VanWagner LB, Ning H, Allen NB, et al. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017; 153:1260.</a></li><li><a class="nounderline abstract_t">Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57:384.</a></li><li><a class="nounderline abstract_t">Moriya A, Iwasaki Y, Ohguchi S, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol 2015; 62:921.</a></li><li><a class="nounderline abstract_t">White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10:1342.</a></li><li><a class="nounderline abstract_t">Thomas JA, Kendall BJ, Dalais C, et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer 2022; 173:250.</a></li><li><a class="nounderline abstract_t">Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13:594.</a></li><li><a class="nounderline abstract_t">Tavakoli H, Robinson A, Liu B, et al. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci 2017; 62:2174.</a></li><li><a class="nounderline abstract_t">Patwardhan V, Paul S, Corey KE, et al. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci 2011; 56:3316.</a></li><li><a class="nounderline abstract_t">Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51:595.</a></li><li><a class="nounderline abstract_t">Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113.</a></li><li><a class="nounderline abstract_t">Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One 2017; 12:e0173499.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021; 385:1559.</a></li><li><a class="nounderline abstract_t">Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57:1357.</a></li><li><a class="nounderline abstract_t">Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7:234.</a></li><li><a class="nounderline abstract_t">Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49:608.</a></li></ol></div><div id="topicVersionRevision">Topic 3600 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226097" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26928243" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pathogenesis of Nonalcoholic Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36727674" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35569886" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27062661" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29404527" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28930295" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28930295" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016382" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734833" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19827166" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414768" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25865049" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22278337" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30796942" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32683103" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15185306" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376042" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059735" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161114" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076987" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545157" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454845" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197789" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192822" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917783" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326299" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37088093" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578268" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625656" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638353" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427778" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162245" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842582" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883485" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537181" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16245220" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23718573" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839868" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955440" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24648894" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17559148" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752837" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135584" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18718471" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503774" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512888" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27322798" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22050199" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26608256" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31006135" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33185364" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19013295" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17410287" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842109" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415840" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22023985" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19009658" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20465434" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18054848" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077838" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25173753" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26749582" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29166236" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26977758" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25935633" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125077" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581244" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880582" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501928" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082596" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long term prognosis of fatty liver: risk of chronic liver disease and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15629518" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17006923" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term follow-up of patients with NAFLD and elevated liver enzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012969" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Natural history of NAFLD: remarkably benign in the absence of cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16502396" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23665288" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24768810" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22446927" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Features, diagnosis, and treatment of nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833486" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Liver fibrosis in overweight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22117531" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19559819" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686698" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22796457" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21987293" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573511" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438497" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393509" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361053" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378307" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633482" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802566" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22521357" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25433160" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Roles of alcohol consumption in fatty liver: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23041539" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35944373" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148760" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28474143" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21805170" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20014114" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012941" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The natural history of nonalcoholic fatty liver disease: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28346543" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34670043" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175136" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19049831" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Long-term follow-up of patients with nonalcoholic fatty liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682312" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
